| Dr James Harold Seals, OD | |
|
1321 Pine Ave, Alma, MI 48801-1242 | |
| (989) 463-1139 | |
| (989) 466-2808 |
| Full Name | Dr James Harold Seals |
|---|---|
| Gender | Male |
| Speciality | Optometrist |
| Location | 1321 Pine Ave, Alma, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972771046 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | JS002928 (Michigan) | Primary |
| Provider Name | James H Seals Peter B Tacia & Tad J Bartz Od Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1740345701 PECOS PAC ID: 5294854105 Enrollment ID: O20110112000326 |
News Archive
Although the medical community has already accepted that colorectal cancer (CRC) screening is cost effective and saves lives, researchers have found that computed tomography colonography (CTC or virtual colonoscopy) not only identifies CRC but also doubles the yield of identifying significant early extracolonic (outside the colon) lesions, resulting in lives saved.
Millions of genetic variants have been discovered over the last 25 years, but interpreting the clinical impact of the differences in a person's genome remains a major bottleneck in genomic medicine. In a paper published in The New England Journal of Medicine on May 27, a consortium including investigators from Brigham and Women's Hospital and Partners HealthCare present ClinGen, a program to evaluate the clinical relevance of genetic variants for use in precision medicine and research.
OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allowance" accepting the Company's application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.
News outlets report that gubernatorial candidates in Florida and Minnesota are offering little details about their plans for health spending.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James Harold Seals, OD 1321 Pine Ave, Alma, MI 48801-1242 Ph: (989) 463-1139 | Dr James Harold Seals, OD 1321 Pine Ave, Alma, MI 48801-1242 Ph: (989) 463-1139 |
News Archive
Although the medical community has already accepted that colorectal cancer (CRC) screening is cost effective and saves lives, researchers have found that computed tomography colonography (CTC or virtual colonoscopy) not only identifies CRC but also doubles the yield of identifying significant early extracolonic (outside the colon) lesions, resulting in lives saved.
Millions of genetic variants have been discovered over the last 25 years, but interpreting the clinical impact of the differences in a person's genome remains a major bottleneck in genomic medicine. In a paper published in The New England Journal of Medicine on May 27, a consortium including investigators from Brigham and Women's Hospital and Partners HealthCare present ClinGen, a program to evaluate the clinical relevance of genetic variants for use in precision medicine and research.
OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allowance" accepting the Company's application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.
News outlets report that gubernatorial candidates in Florida and Minnesota are offering little details about their plans for health spending.
› Verified 1 days ago
State Street Optics Optometrist Medicare: Not Enrolled in Medicare Practice Location: 322 N State St, Alma, MI 48801 Phone: 989-463-1139 | |
Mr. Jacob Zainea, OD Optometrist Medicare: May Accept Medicare Assignments Practice Location: 1321 Pine Ave, Alma, MI 48801 Phone: 989-463-1139 | |
Megan Louise Lark, OD Optometrist Medicare: May Accept Medicare Assignments Practice Location: 1321 Pine Ave, Alma, MI 48801 Phone: 989-463-1139 | |
Great Lakes Eye Institute Optometrist Medicare: Medicare Enrolled Practice Location: 623 W Warwick Dr, Suite 1, Alma, MI 48801 Phone: 989-463-1126 Fax: 989-463-6013 | |
Dr. Kyle Lark, OD Optometrist Medicare: May Accept Medicare Assignments Practice Location: 1321 Pine Ave, Alma, MI 48801 Phone: 989-463-1139 Fax: 989-466-2808 | |
James Seals Peter Tacia Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1321 Pine Ave, Alma, MI 48801 Phone: 989-463-1139 Fax: 989-466-2808 | |
Dr. Garrett W Whitmore, OD Optometrist Medicare: May Accept Medicare Assignments Practice Location: 1321 Pine Ave, Alma, MI 48801 Phone: 989-463-1139 Fax: 989-466-2808 |